Non-cancer therapeutic antibodies

Bibliography

• KOHLER G, MILSTEIN C: Continuous of fused cells secreting antibody of predefined specificity. Nature (1975) 256:465.
   Google Scholar
• GORMAN SD, CLARK MR: of monoclonal antibodies for therapy. Semin. Immunol (1990) 2:457–466.
   PubMedGoogle Scholar
• PASTAN I, FITZGERALD D: toxins for cancer treatment. Science (1991) 254:1173–1177.
   PubMed Web of Science ®Google Scholar
• SPOONER RA, MURRAY S,-BUSZA G, DEONARAIN MP, CHU AC, EPENETOS AA: Genetically engineered antibodies for diagnostic pathology. Hum. Pallid (1994) 25:606–614.
   Google Scholar
• WEINER LM, ADAMS GP: New approaches to antibody therapy. Oncogene (2000) 19:6144–6151.
   PubMed Web of Science ®Google Scholar
• ADAIR JR: Engineering antibodies for therapy. Immunol Rey (1992) 130:5–40.
   PubMedGoogle Scholar
• EHRLICH P: A general review of the recent work in immunity. In: Collected papers of Paul Ehrlich, vol 2 Immunology and cancer research, Pergamon Press, London UK, (1956):442.
   Google Scholar
• VERRIER F, NADAS A, GORNY MK, ZOLLA-PAZNER S: Additive effects characterize the interaction of antibodies involved in neutralisation of the primary dual tropic immunodeficiency virus Type 1 isolate 89.6.1 Vico' (2001) 75:9177–9186.
   Google Scholar
• STAMATATOS L, ZOLLA-PAZNER S, MK, CHENG-MAYER C: Binding of antibodies to viron-associated gp120 molecules of primary-like human immunodeficiency virus Type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology(1997) 229:360–369.
   PubMedGoogle Scholar
• CAVACINI LA, SAMORE MH, J et al.: Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIVType 1 glycoprotein 120. AIDS Res. Hum. Retrovimses (1998) 14:545–550.
   PubMed Web of Science ®Google Scholar
• •First indications of safety and toxicity of an anti-gp120 mAb.
   Google Scholar
• JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. .1. Infect. D (2000) 182:326–329.
   Google Scholar
• •Sustained antiviral effects may be possible with repeated doses.
   Google Scholar
• NAGASHIMA KA, THOMPSON DA, ROSENFIELD SI, MADDON PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus Type 1 entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion.' Infect. D (2001) 183:1121–1125.
   Web of Science ®Google Scholar
• •Evidence of synergy, indicating potential for evaluation of further combinations.
   Google Scholar
• SCARLATTI G, TRESOLDI E, BJORNDAL A et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. (1997) 3:1259–1265.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, REEVES JD, HIBBITTS Set al: Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immuna Rev (2000) 117:112–126.
   Google Scholar
• •Expert overview of coreceptor status and use in HIV infection.
   Google Scholar
• UNUTMAZ D, XIANG W, SUNSHINE MJ, CAMPBELL J, BUTCHER E, LITTMAN DR: The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunoi (2000) 165:3284–3292.
   PubMed Web of Science ®Google Scholar
• SINGH A, BESSON G, MOBASHER A, COLLMAN RG: Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus Type 1 variants from the lungs and blood. " Vim/. (1999) 73:6680–6690.
   PubMedGoogle Scholar
• MORNER A, BJORNDAL A, ALBERT J etal.: Primary human immunodeficiency virus Type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol (1999) 73:2343–2349.
   Google Scholar
• LEE B, LESLIE G, SOILLEUX E et al: tic expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a.Viral. (2001) 75:12028–12038.
   PubMedGoogle Scholar
• WILBANKS A, ZONDLO SC, MURPHY K et al.: Expression cloning of the STRL33/ BONZO/TYMSTR ligand reveals elements of CC, CXC and CX3C chemokines. Immunol (2001) 166:5145–5154.
   Google Scholar
• ZAGURYJF, SILL A, BLATTNER W et al.:to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.J Hum. ViroL (1998) 1:282–292.
   Google Scholar
• RE MC, GIBELLINI D, VITONE F, LA PLACA M: Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review. New Microbial. (2001) 24:197–205.
   PubMedGoogle Scholar
• MHASHILKAR AM, LA VECCHIO J, EBERHARDT B et al.: Inhibition of human immunodeficiency virus Type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanised anti-human immunodeficiency virus Type 1 Tat single-chain variable fragment intrabodies. Hum. Gene Ther (1999) 10:1453–1467.
   PubMedGoogle Scholar
• •Treatment strategy may prove useful, particularly as an adjuvant to antiretroviral therapies.
   Google Scholar
• MARASCO WA, LA VECCHIO J, WINKLER A: Human anti-HIV-1 tat scFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. I Immunol Methods (1999) 231:223–238.
   PubMed Web of Science ®Google Scholar
• •This provocative treatment approach is currently being tested in a clinical gene therapy trial.
   Google Scholar
• RAMSHAW HS, WOODCOCK JM, BAGLEY CJ, MCCLURE BJ, HERCUS TR, LOPEZ AF: New approaches in the treatment of asthma. Immunol Cell Biol. (2001) 79:154–159.
   PubMed Web of Science ®Google Scholar
• •Overview of mAb therapies in asthma.
   Google Scholar
• FAHY JV: Reducing IgE levels as a strategy for the treatment of asthma. Gin. Exp. Allergy (2000) 30\(Suppl. 1):16–21.
   Google Scholar
• STIRLING RG, CHUNG KF: Future treatments of allergic diseases and asthma. Br. Med. Bull. (2000) 56:1037–1053.
   PubMed Web of Science ®Google Scholar
• BOUSHEY HA: Experiences with monoclonal antibody therapy for allergic asthma. I Allergy Clin. Immunol (2001) 108:S77–83.
   PubMed Web of Science ®Google Scholar
• •Overview of mAb therapies in allergic asthma.
   Google Scholar
• BUSSE W, CORREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanised monoclonal antibody, for the treatment of severe allergic asthma." Allergy Chit Immunol (2001) 108:184–190.
   Google Scholar
• MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108:E36.
   PubMed Web of Science ®Google Scholar
• ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanised mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol (2000) 106:253–259.
   PubMed Web of Science ®Google Scholar
• RUDOLF MP, ZUERCHER AW, NECHANSKY A et al.: Molecular basis for non anaphylactogenicity of a monoclonal anti-IgE antibody. I Immunol (2000) 165:813–819.
   PubMed Web of Science ®Google Scholar
• RABE KF, WATSON N, DENT G et al: of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9. Am. J. Respir. Grit. Care Med. (1998) 157:1429–1435.
   PubMed Web of Science ®Google Scholar
• RACINE-POON A, BOTTA L, CHANG TW et al: Efficacy, pharmacodynamics and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol The,: (1997) 62:675–690.
   Google Scholar
• VAN NEERVEN RI, VAN ROOMEN CP, THOMAS WR, DE BOER M, KNOL EF, DAVIS FM: Humanised anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells. Int. Arch. Allergy Immunol. (2001) 124:400–402.
   PubMedGoogle Scholar
• LECKIE MJ TEN BRINKE A, KHAN Jet al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet (2000) 356:2144–2148.
   PubMedGoogle Scholar
• •Demonstrates the effectiveness of anti-1L5 approaches.
   Google Scholar
• HART TK, COOK RM, ZIA-AMIRHOSSEINI P et al.: Preclinical efficacy and safety of mepolizumab (SB-240563), a humanised monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol (2001) 108:250–257.
   PubMed Web of Science ®Google Scholar
• BERTRAND CP, PONATH PD: CCR3 blockade as a new therapy for asthma. Expert Opin. Investig. Drugs (2000) 9(1):43–52.
   PubMed Web of Science ®Google Scholar
• TERADA N, HAMANO N, KIM WJ et al.: The kinetics of allergin-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am. I Respic Crit. Care Med. (2001) 164:575–579.
   PubMedGoogle Scholar
• REMBERGER M, SVAHN BM, HENTSCHKE P, LOFGREN C, RINGDEN 0: Effect of cytokine release and graft- versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell. Bone Marrow Transplant. (1999) 24:823–830.
   PubMed Web of Science ®Google Scholar
• BURK ML, MATUSZEWSKI KA: Muromononab-CD3 and antithymocyte globulin in renal transplantation. (1997) Ann. Pharmacother. 31: 1370–1377.
   Google Scholar
• YU XZ, BIDWELL SJ, MARTIN PJ, ANASETTI C: Anti-CD3 epsilon F(ab')2 prevents graft- versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. Immunol (2001) 166:5835–5839.
   Google Scholar
• CIBRIK DM, KAPLAN M, MEIER-KRIESCHE HU: Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs (2001) 15:665–666.
   Google Scholar
• SIMPSON D: New developments in the prophylaxis and treatment of graft versus host disease. Expert Opin. Pharmacother. (2001) 2:1109–1117.
   PubMedGoogle Scholar
• •Extensive review on the treatment of GVHD.
   Google Scholar
• CARSWELL CI, PLOSKER GL, WAGSTAFF AJ: Daclizumab: a review of its use in the management of organ transplantation. BioDrugs (2001) 15:745–773.
   PubMed Web of Science ®Google Scholar
• BUMGARDNERGL, HARDIE I, JOHNSON RW et al: Results of 3-year Phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantion. Transplantation (2001) 72:839–845.
   PubMedGoogle Scholar
• BELL J, COLANERI J: Basiliximab (Simulect): simplifying induction therapy. Nephrol Nurs. .1. (2000) 27:243-244.
   Google Scholar
• WISEMAN LR, FAULDS D: Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs (1999) 58:1029–1042.
   PubMed Web of Science ®Google Scholar
• ONRUSTSV, WISEMAN LR: Basilixumab. Drugs (1999) 57:207–213.
   PubMedGoogle Scholar
• WOOD MJ, SLOAN DJ, WOOD KJ, CHARLTON HM: Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Neuroscience (1996) 70:775–789.
   PubMedGoogle Scholar
• HONEY K, COBBOLD SP, H: Dominant tolerance and linked suppression induced by therapeutic antibodies do not depend on Fas-FasL interactions. Transplantation (2000) 69:1683–1689.
   PubMedGoogle Scholar
• OSSEVOORT MA, RINGERS J, KUHN EM et al.: Prevention of renal allograft rejection in primates by blocking the B7/28 pathway. Transplantation (1999) 68:1010–1018.
   PubMed Web of Science ®Google Scholar
• KIRK AD, TADAKI DK, CELNIKER A et al.: Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation (2001) 72:377–384.
   PubMed Web of Science ®Google Scholar
• GARCA L, HONEY K, ADAMS E, COBBOLD SP, WALDMANN H: Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.. (2000) 165:4785–4786.
   Google Scholar
• GOBBURU JV, TENHOOR C, ROGGE MC et al.: Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. J. Pharmacol Exp. Ther. (1998) 286:925–930.
   PubMedGoogle Scholar
• •Awaiting results of Phase I-II clinical trials.
   Google Scholar
• NIZET Y, CHENTOUFI AA, DE LA PARRA B et al: The experimental (fti vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. Transplantation (2000) 69:1420–1428.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, BLAZAR BR, BOLWELL BJ et al.: Treatment of steroid-refractory acute graft- versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood (2001) 98:2052–2058.
   PubMed Web of Science ®Google Scholar
• •First but not last study with anti-CD147 mAb.
   Google Scholar
• HERICOURT J, RICHET C: Thysiologie Pathologique'-de la serotherapie dans le traitement du cancer. C. r. hebd. Seanc. Acad. ScL Paris. (1985) 121:567.
   Google Scholar
• CASADEVALL A, SCHARFF MD: Return to the past: the case for antibody-based therapies in infectous diseases. Gin. Infect. Dis. (1995) 21:150–161.
   PubMed Web of Science ®Google Scholar
• GREENOUGH A, THOMAS M: Respiratory syncytial virus prevention: past and present strategies. Expert Opin. Pharmacother. (2000) 1:1195–1201.
   PubMedGoogle Scholar
• AMERICAN ACADEMY OF PEDIATRICS COMMITTEE ON INFECTIOUS DISEASES AND COMMITTEE OF FETUS AND NEWBORN: Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics (1998) 102:1211–1216.
   PubMed Web of Science ®Google Scholar
• No authors listed. Palivizumab in prevention of bronchiolitis: new preparation. Moderate efficiacy in some. Prescire Int. (2000) 9:171–172.
   PubMedGoogle Scholar
• TERRYBERRY JW, SHOENFELD Y, SHERER Y et al.: Detection of antibodies to gangliosides and glycoproteins in various intravenous immunoglobulin (IVIg) preparations. Immunol Invest. (2000) 29:337–347.
   PubMed Web of Science ®Google Scholar
• HAMMOND D: CytoGam infusions at home. J. Litraven. Nurs. (1999) 22:331–335.
   Google Scholar
• LLOYD-EVANS P, GILMOUR JE: Expression of neutralising recombinant human antibodies against Varicella Zoster virus for use as a potential prophylactic. Hybridoma. (2000) 19:143–149.
   PubMedGoogle Scholar
• CHAMPION JM, KEAN RB, CE et al.: The development of monoclonal human rabies virus-neutralising antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J. Immunol Methods (2000) 235:81–90.
   PubMed Web of Science ®Google Scholar
• VAN NUNEN AB, BAUMANN M, MANNS MP et al.: Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver (2001) 21:207–212.
   PubMedGoogle Scholar
• ANGUS DC, BIRMINGHAM MC, BALK RA et al: E5 murine monoclonal anti endotoxin antibody in Gram-negative sepsis: a randomised controlled trial. E5 study investigators. JAMA. (2000) 283:1723–1730.
   Google Scholar
• DERKX B, WITTES J, MCCLOSKEY R: Randomised, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European parediatric meningococcal septic shock trial study group. Clin. Infect. Dis. (1999) 28:770–777.
   PubMed Web of Science ®Google Scholar
• HELPER DJ, REX DK: Inflammatory bowel disease. Endoscopy (2001) 33:140–106.
   PubMed Web of Science ®Google Scholar
• HAMILTON K, CLAIR EW: Tumour necrosis factor-alpha: a new era for effective management of rheumatoid arthritis. Expert Opin. Pharmacothei: (2000) 1:1041–1052.
   PubMedGoogle Scholar
• LIPSKY PE, VAN DER HEIJDE DM et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl. J. Med (2000) 343:1594–1602.
   Google Scholar
• MORELAND LW, COHEN SB, BAUMGARTNER SW et al.: Long-term and efficacy of Etanercept in patients with rheumatoid arthritis. J. Rheumatol (2001) 28:1238–1244.
   PubMed Web of Science ®Google Scholar
• AGNHOLT J, KALTOFT K: Infliximabdownregulates interferon-gamma production in activated gut-lymphocytes from patients with Crohn's disease. Cytokine (2001) 15:212–222.
   PubMed Web of Science ®Google Scholar
• SERRANO MS, SCHMIDT-SOMMERFELD E, KILBAUGH TJ, BROWN RF, UDALL JN, MANNICK EE: Use of Infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. (2001) 35:823–828.
   PubMed Web of Science ®Google Scholar
• VALLE E, GROSS M, BICKSTON SJ: Infliximab. Expert Opin. Pharmacother. (2001) 2:1015–1025.
   PubMedGoogle Scholar
• •Extensive review of Infliximab.
   Google Scholar
• ALLDRED A: Etanercept in rheumatoid. Expert Opin. Pharmacother. (2001) 2:1137–1148.
   PubMedGoogle Scholar
• •Extensive overview of Etanercept.
   Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088–1094.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC: Anti-tumour necrosis factor therapies. (2001) Carr: Opin. Rheumatol (2001) 13:164–169.
   Google Scholar
• •Overview encompassing all anti-TNF approaches.
   Google Scholar
• KEYSTONE EC: Tumour necrosis factor-a blockade in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2001) 27:427–443.
   PubMed Web of Science ®Google Scholar
• BARRERA P, JOOSTEN LA, DEN BROEDER AA, VAN DE PUTTE LB, VAN RIEL PL, VAN DEN BERG WB: Effects of treatment with a fully human anti-tumour necrosis factor a monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF a in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2001) 60:660–669.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Antitumour necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Liflamm. Bowel Dis. (1999) 5:119–133.
   PubMed Web of Science ®Google Scholar
• •Extensive review of IBD treatment with anti-TNF agents.
   Google Scholar
• SANDBORN WJ, FEAGAN BG, HANAUER SB et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomised-blind placebo-controlled trial. Gastroenterology (2001) 120:1330–1338.
   PubMed Web of Science ®Google Scholar
• RAZA A: Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis and myelodysplasic syndromes. Microsc. Res. Tech. (2000) 50:229–235.
   PubMed Web of Science ®Google Scholar
• SIMON LS, YOCUM D: New and future drug therapies for rheumatoid arthritis. Rheumatology (2000) 39 (Suppl. 1):36–42.
   Google Scholar
• CHOY EH, CONNOLLY DJ, RAPSON N et al.: Pharmacokinetic, pharmacodynamic and clinical effects of a humanised IgG1 anti- CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (2000) 39:1139–1146.
   PubMedGoogle Scholar
• MOULD DR, DAVIS CB, MINTHORN EA et al.: A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. (1999) 66:246–257.
   PubMed Web of Science ®Google Scholar
• VEALE DJ, REECE RJ, PARSONS Wet al.: Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthoscopy, magnetic resonance imaging and histology. Ann. Rheum. D AK (1999) 58:342–349.
   Google Scholar
• YOCUM DE, SOLINGER AM, TESSERJ et al.: Clinical and immunological effects or a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a Phase I, single dose, dose escalating trial. ./. Rheumatol (1998) 25:1257–1262.
   PubMed Web of Science ®Google Scholar
• SCHULZE-KOOPS H, DAVIS LS, HAVERTY TP, WACHOLTZ MC, LIPSKY PE: Reduction of Thl cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanised monoclonal antibody to CD4..1. Rheumatol. (1998) 25:2065-2076..LADUCA JR, GASPARI AA: Targeting necrosis factor a. New drugs used to modulate inflammatory diseases. Dermatol. Clin (2001) 19:617–635.
   Google Scholar
• MEASE PJ, GROFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• BROK HP, TEKOPPELE JM, HAKIMI J et al.: Prophylactic and therapeutic effects of a humanised monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on-induced arthritis (CIA) in rhesus. Clin. Exp. Immunol. (2001) 124:134–141.
   PubMed Web of Science ®Google Scholar
• KRUGER JG, WALTERS IB, MIYAZAWA et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanised anti-Tac antibody to patients with psoriasis. .1. Am. Acad. Dermatol (2000) 43:448–458.
   Google Scholar
• •Suggestion that Dadizurnab may gain indication in psoriasis.
   Google Scholar
• SCHOPF RE: IDEC-114 (IDEC). Carr: Opin. Investig. Drugs (2001) 2:635–638.
   Google Scholar
• BREEDVELD FC: Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology (1999) 38\(Suppl. 2):11–13.
   Google Scholar
• WILLIAMS KC, ZHAO W, POLITOPOULOU G, MALE D, HICKEY WF: Inhibition of experimental allergic encephalomyelitis with an antibody that recognizes a novel antigen expressed on lymphocytes, endothelial cells and microglia. Lab. Invest. (2000) 80:313–326.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEN BW, LAI M, GKINSON S et al.: Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomised, double-blind, placebo-controlled, MR-monitored Phase II trial. Neurology (1997) 49:351–357.
   PubMed Web of Science ®Google Scholar
• ASAKURA K, MILLER DJ, PEASE LR, RODRIGUEZ M: Targeting of IgM kappa antibodies to oligodendrocytes promotes CNS remyelination. Neurosci (1998) 18:7700–7708.
   PubMed Web of Science ®Google Scholar
• WARRINGTON AE, ASAKURA K, BIEBER AJ et al.: Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA (2000) 97:6820–6825.
   PubMed Web of Science ®Google Scholar
• POEHLAU D, FEDERLEIN J, POSTERT T et al.: Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis-outline of a double-blind randomised, placebo-controlled trial. Mult. Sclei: (1997) 3:149–152.
   PubMedGoogle Scholar
• POEHLAU D: Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins - interim results on drug safety of an ongoing study. IVIG study group. Mult. Scler. (2000) 6\(Suppl. 2):521–523.
   Google Scholar
• WEINSTOCK-GUTTMAN B, JACOBS LD: What is new in the treatment of sclerosis? Drugs (2000) 59:401–410.
   PubMed Web of Science ®Google Scholar
• PORRINI AM, DE LUCA G, GAMBI D, REDER AT: Effects of an anti-IL-10 monoclonal antibody on rIFN13-1b-mediated immune modulation. Relevance to multiple sclerosis. J. Neuraimmuna (1998) 81:109–115.
   Google Scholar
• BOON L, BROK HP, BAUER J et al: Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. Immunol (2001) 167:2942–2949.
   Google Scholar
• •Reduced clinical, pathological and radiological aspects of EAE in predinical model points to therapeutic potential in MS.
   Google Scholar
• HOWARD LM, MIGA AJ, CL et al: Mechanisms of immunotherapeutic intervention by anti-CD4OL (CD154) antibody in an animal model of multiple sclerosis. Clin. Invest. (1999) 103:281–290.
   Google Scholar
• •Promising irnmunotherapeutic strategy for treatment of ongoing T-cell mediated autoirnmune diseases.
   Google Scholar
• VAN OOSTEN BW, BARKHOF F, TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 46:1531–1534.
   Google Scholar
• THE LANERCEPT MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: TNF neutralisation in MS: results of a randomised, placebo-controlled multicentre study. Neurology (1999) 53:457–465.
   PubMed Web of Science ®Google Scholar
• ARNETT HA, MASON J, MARINO M, SUZUKI K, MATSUSHIMA GK, TING JP: TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. (2001) 4:1116–1122.
   PubMed Web of Science ®Google Scholar
• •Indicates that TNFR2 and not TNER1 is critical for oligodendrocyte regeneration.
   Google Scholar
• VAN NUNEN AB, BAUMANN M, MANNS MP et al.: Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver (2001) 21:207–212.
   PubMedGoogle Scholar
• •Anti-IgE exerts effect not only on inhibition of mast cell/basophil degranulation but also on T-cell activation.
   Google Scholar
• BARD F, CANNON C, BARBOUR R et al.: Periphally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzehimer disease. Nat. Med. (2001) 6:916–919.
   Google Scholar
• •Adds further weight to the application of antibody based therapeutic approaches for AD.
   Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Al3 peptide vaccination prevents memory loss in an animal model of Alzehimer's disease. Nature (2000) 408:982–985.
   PubMed Web of Science ®Google Scholar
• •Important indication that antibody based therapy of AD may be effective.
   Google Scholar
• LIEKENS S, DE CLERCQ E, NEYTS J: Angiogenesis: regulators and clinical applications. Biochem. Pharmacol (2001) 61:253–270.
   PubMed Web of Science ®Google Scholar
• •Clinical application of various anti-angiogenic factors.
   Google Scholar
• POSEY JA, KHAZAELI MB, DELGROSSO A et al: A pilot trial of Vitaxin, a humanised anti-vitronectin receptor (anti avI33) antibody in patients with metastatic cancer. Cancer Biotite]: Radiopharm. (2001) 16:125–132.
   PubMed Web of Science ®Google Scholar
• •Suggests that Vitaxin Tm may have non-cancer application.
   Google Scholar
• MIKECZ K: Vitaxin applied molecular evolution. Curr: Opin. Invest. Drugs (2000) 1:199–203.
   PubMedGoogle Scholar
• •Suggestion of multiple application of VitaxinTm.
   Google Scholar
• TRUONG KM, AMANKWA K, KUCUKARSLAN S: Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Clin. Ther. (2001) 23:1145–1165.
   PubMedGoogle Scholar
• COHEN SA, TRIKHA M, MASCELLI MA: Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol OncoL Res. (2000) 6:163–174.
   PubMedGoogle Scholar
• DANGAS G, BADIMON JJ, COLLER BS et al.: Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler. Thromb. Vase. Biol. (1998) 18:1342–1349.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, GUSTO IV-ACS INVESTIGATORS: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357:1915–1924.
   PubMed Web of Science ®Google Scholar
• •Indicates that abciximab is not beneficial as first-line treatment in patients with acute coronary syndromes.
   Google Scholar
• SCHWEIZER J, KIRCH W, KOCH R, MULLER A, HELLNER G, FORKMANN L: Short- and long-term results of abciximab versus asprin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology (2000) 51:913–923.
   PubMedGoogle Scholar
• •Abcixirnab plus thrombolytic agent may provide synergy.
   Google Scholar
• THE ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605–613.
   PubMedGoogle Scholar
• •Combination therapies for MI.
   Google Scholar
• RUSNAK JM, KOPECKY SL, CLEMENTS IP et al.: An anti-CD11/ CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am. Cardiol (2001) 88:482–487.
   PubMed Web of Science ®Google Scholar
• •Hu23F2G appears safe and well tolerated, suggests further clinical evaluation.
   Google Scholar
• SCHNEIDER D, BERROUSCHOT J, BRANDT T et al: Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Ear: Neurol (1998) 40:78–83.
   PubMed Web of Science ®Google Scholar
• •First indications of anti-ICAM-1 antibody approaches.
   Google Scholar
• FITCH JC, ROLLINS S, MATIS L et al.: Pharmacology and biological efficacy of a recombinant, humanised, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery pass graft surgery with cardiopulmonary bypass. Circulation (1999) 100:2499–2506.
   PubMed Web of Science ®Google Scholar
• WEISS L, SLAVIN S, REICH S et al: Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. USA. (2000) 97:285–290.
   PubMed Web of Science ®Google Scholar
• •Diabetes.
   Google Scholar
• THATTE U: AN-1792 (Elan). Curr: Opin. Invest. Drugs (2001) 2:663–667.
   Google Scholar
• •Data from Phase II trial currently due.
   Google Scholar
• FRENKEL D, SOLOMON B, BENHAR: Modulation of Alzehimer's P-amyloid neurotoxicity by site directed single-chain antibody. J. Neuroimmunol (2000) 106:23–31.
   PubMed Web of Science ®Google Scholar
• •Intracellular expression vectors down regulating Ab deposition offer another AD therapeutic approach.
   Google Scholar